Eli Lilly Navigates Pricing Pressures Amidst Competitive Landscape
PILLAR DIAGNOSTIC // WEEK 09
“Novo’s planned semaglutide price cuts and intensifying GLP-1 competition are erecting a hard ceiling on obesity-drug pricing just as Lilly’s Mounjaro/Zepbound volume ramps according to the machine, and with no clear institutional follow-through in the tape for Lilly yet, the stock is vulnerable to a near-term pullback once the market fully absorbs the pricing headwind.”
Proposed action
Avoid chasing further upside in Lilly; consider trimming or hedging near-term exposure until pricing clarity emerges.
THE MECHANICS
Tape & flow
Novo Nordisk’s stock plunged about 15–16% as forced selling followed trial results showing CagriSema trailed Eli Lilly’s Zepbound, which lists at $1,086.37, while Lilly shares rallied and Bristol-Myers Squibb also gained.
THE MACHINE
Operational momentum
Mounjaro and Zepbound demand is surging, contributing over 50% of total revenues and driving year-on-year growth above 40%; Lilly is ramping production with more than $9.5 billion in new U.S. investment, rolling out four-dose KwikPens, advancing orforglipron for a mid-2026 launch, and guiding 2026 revenues of $80–83 billion.
THE MAP
Structure & constraints
Global regulatory reviews are advancing for oral and injectable obesity and immunology therapies, with orforglipron filed in 40+ countries and CHMP support for Olumiant’s adolescent alopecia areata indication, while Novo Nordisk’s planned U.S. semaglutide price cuts and rising GLP-1 competition intensify pricing and market structure pressures. Supply chains are diversifying—Lilly is using India as a global export hub—and tax regimes diverge sharply between its Ireland and U.S. obligations.
THE MOOD
Consensus & positioning
A trial setback for Novo Nordisk’s CagriSema has sown disappointment and cast doubt on the company’s obesity-drug growth narrative, while bolstering investor conviction in Eli Lilly’s leadership, efficacy edge and expanding GLP-1 pipeline. Enthusiasm around Lilly’s product innovations and market positioning contrasts with lingering nervousness over lofty expectations and valuation risks.
